🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "huge turning point" in the fight against superbug strains of the pathogen, according to researchers.

A Global Public Health Issue

Gonorrhoea infections are increasing worldwide, with data suggesting in excess of 82 million new cases each year. Particularly high rates are seen in the African continent and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary step in the reality of growing infection rates, escalating drug resistance and the highly restricted therapeutic options at this time.”

Health officials are particularly alarmed about the surge in drug-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance showed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Drugs Gain Approval

One new antibiotic, marketed under the name a brand name, was cleared by the US Food and Drug Administration in December for use against gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Experts believe that focused deployment of this new drug will help delay the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, was also approved in concurrent days. This drug, which is additionally indicated for UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin emerged from a innovative non-profit model for drug creation. The charitable organization GARDP worked alongside the drug firm its industry partner to develop it.

“This milestone marks a major breakthrough in the therapy of superbug gonorrhoea, which until now has been staying ahead of medical innovation.”

Testing Data and Worldwide Availability

According to results detailed in a prominent scientific publication, the new drug successfully treated over nine in ten of uncomplicated infections. This places it at an similar efficacy with the existing first-line therapy, which uses an injection and a pill. The study involved over 900 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the ability to register and commercialise the drug in many low-income and middle-income countries.

Clinicians directly involved have shared optimism. The availability of a easy-to-administer therapy of this kind is seen as a "critical tool" for public health efforts. This is deemed essential to lessen the impact of the infection for people and to stop the proliferation of extremely resistant gonorrhoea globally.